# Raynovent

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/raynovent

- Industry: Biotechnology
- Headquarters: Guangzhou, China
- Website: www.raynovent.com
- Total disclosed funding: $117M
- Latest round: Series C (Dec 30, 2022)
- Investors on record: 11

## About

Based in Guangdong, China and founded in 2018, Guangdong Raynovent Biotech Co., Ltd., dba Raynovent, is a biotechnology company engaged in developing and commercializing innovative drug pipelines for respiratory and metabolic diseases. The company was formed by and operates as a subsidiary of Zhongsheng Pharma, a pharmaceutical company listed on Shenzhen Stock Exchange. Raynovent's founder, Chaofeng Long, holds a master's degree of Clinical Pharmacology from Beijing Medical University.

In August 2026, Zhongsheng Pharma announced to acquire a 12.06 % minority stake in Raynovent from Lake Bleu Capital, Snow Owl, LLC and BioTrack Capital for over USD 28.26 million.

Raynovent focuses on the research and development of innovative drug for the treatment of respiratory and metabolic diseases such as Influenza, Primary Biliary Cholangitis (PBC), Nonalcoholic steatohepatitis (NASH) and Avian Influenza.

The company generates revenue from developing innovative drugs for respiratory and metabolic diseases.

## Funding rounds

- Series C, Dec 30, 2022, $54M — Efung Capital, Guangzhou Guoju Venture Capital, Lake Bleu Capital, Wanlian Guangsheng Investment
- Series B, Dec 16, 2020, $43M — BOCOM International Asset Management, Efung Capital, Huatai Zijin Investment, Yijing Investment, BioTrack Capital, Lake Bleu Capital, CITIC Med Fund, Zhongsheng Pharmaceutical
- Series A, Aug 2, 2019, $4.2M — BioTrack Capital
- Series A, Jan 10, 2019, $16M — Lake Bleu Capital, Snow Owl, LLC

## Investors

- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series A, Series B, Series C
- Snow Owl, LLC — Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A, Series B
- BOCOM International Asset Management (https://capitalatlas.ai/funds/bocom-international-asset-management) — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B, Series C
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series B
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series B
- CITIC Med Fund (https://capitalatlas.ai/funds/citic-med-fund) — Series B
- Zhongsheng Pharmaceutical — Series B
- Guangzhou Guoju Venture Capital (https://capitalatlas.ai/funds/guangzhou-guoju-venture-capital) — Series C
- Wanlian Guangsheng Investment — Series C